131 related articles for article (PubMed ID: 38846999)
21. IMMUNOPHENOTYPE OF LEUKEMIC CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH NOTCH1 AND SF3B1 GENE MUTATIONS.
Golyarnik N; Абраменко І; Movchan G; Martina Z; Dyagil I; Chumak A; Bazyka D
Exp Oncol; 2023 Dec; 45(3):322-327. PubMed ID: 38186023
[TBL] [Abstract][Full Text] [Related]
22. Full-length transcript characterization of SF3B1 mutation in chronic lymphocytic leukemia reveals downregulation of retained introns.
Tang AD; Soulette CM; van Baren MJ; Hart K; Hrabeta-Robinson E; Wu CJ; Brooks AN
Nat Commun; 2020 Mar; 11(1):1438. PubMed ID: 32188845
[TBL] [Abstract][Full Text] [Related]
23. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
24. SF3B1 is a stress-sensitive splicing factor that regulates both HSF1 concentration and activity.
Kim Guisbert KS; Guisbert E
PLoS One; 2017; 12(4):e0176382. PubMed ID: 28445500
[TBL] [Abstract][Full Text] [Related]
25. The Development and Use of Scalable Systems for Studying Aberrant Splicing in SF3B1-Mutant CLL.
Murthy T; Paul KV; Minella AC; Pillai MM
Methods Mol Biol; 2019; 1881():83-99. PubMed ID: 30350199
[TBL] [Abstract][Full Text] [Related]
26. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
[TBL] [Abstract][Full Text] [Related]
27. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
[TBL] [Abstract][Full Text] [Related]
28. Modulation of RNA splicing associated with Wnt signaling pathway using FD-895 and pladienolide B.
Kumar D; Kashyap MK; Yu Z; Spaanderman I; Villa R; Kipps TJ; La Clair JJ; Burkart MD; Castro JE
Aging (Albany NY); 2022 Mar; 14(5):2081-2100. PubMed ID: 35230971
[TBL] [Abstract][Full Text] [Related]
29. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia.
Xargay-Torrent S; López-Guerra M; Rosich L; Montraveta A; Roldán J; Rodríguez V; Villamor N; Aymerich M; Lagisetti C; Webb TR; López-Otín C; Campo E; Colomer D
Oncotarget; 2015 Sep; 6(26):22734-49. PubMed ID: 26068951
[TBL] [Abstract][Full Text] [Related]
30. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
[TBL] [Abstract][Full Text] [Related]
31. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
Kim Guisbert KS; Mossiah I; Guisbert E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
[TBL] [Abstract][Full Text] [Related]
32. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
33. [Understanding and therapeutic targeting of aberrant mRNA splicing mechanisms in oncogenesis].
Tanaka A; Kobayashi S; Xiao M; Inoue D
Rinsho Ketsueki; 2020; 61(6):643-650. PubMed ID: 32624538
[TBL] [Abstract][Full Text] [Related]
34.
Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
[TBL] [Abstract][Full Text] [Related]
35. NOTCH1, SF3B1, MDM2 and MYD88 mutations in patients with chronic lymphocytic leukemia.
Maleki Y; Alahbakhshi Z; Heidari Z; Moradi MT; Rahimi Z; Yari K; Rahimi Z; Aznab M; Ahmadi-Khajevand M; Bahremand F
Oncol Lett; 2019 Apr; 17(4):4016-4023. PubMed ID: 30930998
[TBL] [Abstract][Full Text] [Related]
36. Chemical Inhibition of Pre-mRNA Splicing in Living Saccharomyces cerevisiae.
Hansen SR; Nikolai BJ; Spreacker PJ; Carrocci TJ; Hoskins AA
Cell Chem Biol; 2019 Mar; 26(3):443-448.e3. PubMed ID: 30639260
[TBL] [Abstract][Full Text] [Related]
37. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
38. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
39. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
40. An important class of intron retention events in human erythroblasts is regulated by cryptic exons proposed to function as splicing decoys.
Parra M; Booth BW; Weiszmann R; Yee B; Yeo GW; Brown JB; Celniker SE; Conboy JG
RNA; 2018 Sep; 24(9):1255-1265. PubMed ID: 29959282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]